Creativ-Ceutical is now part of our team. Learn more here.
Log in or register to see all Alerts
Log in Register
Market Access Alerts >December 2021>Germany
New HTA Decisions in Germany
December 2021
Drug name
EVRENZO® (roxadustat)
Company
Astellas Pharma GmbH
Decision date
15/12/2021
About PHMR
Therapeutic area
Kidney conditions
Therapeutic sub area
Chronic kidney disease
G-BA decision date
01/03/2022
Orphan Drug?
No
Decision
No additional benefit
Indication
Adults with symptomatic anaemia in chronic kidney disease who have not previously been treated with an erythropoiesis-stimulating agent (ESA), or who are being switched from an ESA; of which adults only stably pre-treated with an ESA are suitable for switching. Appropriate comparator therapy: ESA
Decision Detail
Main driver of decision: There were no relevant RCTs identified for the benefit assessment of roxadustat in comparison with the ACT. Therefore, no suitable data was available for the benefit assessment.
Summary
IQWIG concluded that there was no added benefit.


PHMR
Berkeley Works
Berkley Grove
London
NW1 8XY

+44 (0)20 3432 7450

info@phmr.com


 Understanding Payers

 Generating Evidence

 Developing Strategies

 Communicating Value

 Market Access Alerts

 Careers

 About us

 Contact us

 Cookie policy

 Privacy